TABLE 2.
Weighted Percent Distribution of Type of Initial Therapy Received for Men With Nonmetastatic Prostate Cancer by Demographic, Residential, and Clinical Characteristics; CDC Breast and Prostate Patterns of Care Study
| Selected Characteristics | Total (N [%])* | Type of Initial Therapy
|
|||||
|---|---|---|---|---|---|---|---|
| RP (%)* | EBRT (%)* | BT/BT + EBRT (%)* | PADT (%)* | AS (%)* | NT (%)* | ||
| All localized cases | 8229 (100.0) | 43.6 | 19.9 | 16.0 | 6.9 | 4.7 | 9.0 |
| Demographic variables | |||||||
| Age group | |||||||
| < 60 | 2169 (100.0) | 70.4 | 8.4 | 11.4 | 0.8 | 2.0 | 6.9 |
| 60–64 | 1444 (100.0) | 58.4 | 14.4 | 15.3 | 3.2 | 2.7 | 5.9 |
| 65–69 | 1681 (100.0) | 43.0 | 21.0 | 20.6 | 3.2 | 3.0 | 9.2 |
| 70–74 | 1390 (100.0) | 25.7 | 32.6 | 20.9 | 5.8 | 3.9 | 11.1 |
| 75 + | 1545 (100.0) | 9.5 | 28.0 | 13.8 | 23.6 | 12.7 | 12.4 |
| Race/ethnicity | |||||||
| Non-Hispanic white | 4822 (100.0) | 46.0 | 18.5 | 16.9 | 6.1 | 4.8 | 7.7 |
| African American | 2444 (100.0) | 35.6 | 24.5 | 15.5 | 9.0 | 3.8 | 11.6 |
| Hispanic | 570 (100.0) | 39.0 | 21.9 | 8.4 | 10.2 | 5.2 | 15.2 |
| Asian/other | 393 (100.0) | 40.3 | 24.6 | 13.3 | 4.8 | 5.9 | 10.9 |
| Marital status | |||||||
| Married | 5965 (100.0) | 46.4 | 19.5 | 16.7 | 5.1 | 4.5 | 7.8 |
| Single/Divorced/Separated/Widowed | 1794 (100.0) | 35.0 | 22.5 | 16.2 | 10.4 | 4.4 | 11.5 |
| Unknown | 470 (100.0) | 37.2 | 16.1 | 6.5 | 17.3 | 7.8 | 15.0 |
| State | |||||||
| A | 1467 (100.0) | 41.2 | 22.6 | 9.9 | 8.0 | 4.9 | 13.3 |
| B | 1729 (100.0) | 33.9 | 22.3 | 28.2 | 4.0 | 2.9 | 8.8 |
| C | 494 (100.0) | 49.0 | 19.8 | 14.0 | 5.6 | 2.9 | 8.6 |
| D | 1618 (100.0) | 37.7 | 18.0 | 17.2 | 12.8 | 5.5 | 8.7 |
| E | 918 (100.0) | 55.1 | 14.0 | 12.0 | 6.1 | 6.9 | 5.9 |
| F | 989 (100.0) | 44.4 | 22.0 | 16.8 | 5.6 | 5.3 | 6.0 |
| G | 1014 (100.0) | 51.1 | 15.0 | 15.0 | 6.8 | 3.9 | 8.3 |
| Insurance coverage | |||||||
| Private | 4787 (100.0) | 51.7 | 15.8 | 16.2 | 4.0 | 3.8 | 8.4 |
| Medicaid | 600 (100.0) | 31.5 | 21.9 | 12.7 | 15.5 | 3.6 | 14.7 |
| Medicare, other public | 2326 (100.0) | 28.2 | 27.9 | 17.5 | 10.7 | 6.9 | 8.8 |
| None | 134 (100.0) | 49.0 | 23.0 | 7.9 | 8.8 | 3.0 | 8.3 |
| Unknown | 382 (100.0) | 41.3 | 22.5 | 11.3 | 10.4 | 4.8 | 9.6 |
| Residential variables | |||||||
| Urban/rural residence* | |||||||
| 100% urban | 3985 (100.0) | 43.5 | 19.1 | 15.3 | 6.8 | 5.0 | 10.2 |
| 100% rural | 1313 (100.0) | 39.2 | 23.1 | 15.5 | 7.7 | 5.6 | 8.9 |
| Rural/urban mix | 2900 (100.0) | 45.8 | 19.7 | 17.3 | 6.6 | 3.7 | 6.8 |
| Working CLASS | |||||||
| < 66% in working class | 3322 (100.0) | 48.2 | 17.5 | 16.5 | 5.0 | 4.6 | 8.1 |
| 66% + in working class | 4875 (100.0) | 39.8 | 21.9 | 15.6 | 8.5 | 4.7 | 9.4 |
| Poverty level | |||||||
| < 20% below poverty level | 6185 (100.0) | 46.1 | 19.0 | 16.4 | 5.8 | 4.6 | 8.1 |
| 20 + % in poverty level | 2012 (100.0) | 32.1 | 24.2 | 14.6 | 11.8 | 5.1 | 12.2 |
| Educational attainment | |||||||
| < 25% without HS education | 5026 (100.0) | 48.1 | 17.6 | 16.4 | 5.3 | 4.9 | 7.7 |
| 25 + % without HS education | 3171 (100.0) | 34.2 | 24.8 | 15.2 | 10.3 | 4.2 | 11.2 |
| Socioeconomic status | |||||||
| High | 4790 (100.0) | 48.3 | 17.6 | 16.5 | 5.2 | 4.8 | 7.6 |
| Middle | 1631 (100.0) | 37.9 | 23.3 | 15.4 | 8.5 | 4.2 | 10.6 |
| Low | 1776 (100.0) | 30.7 | 25.4 | 14.7 | 12.3 | 4.7 | 12.2 |
| Clinical variables | |||||||
| Comorbidity severity | |||||||
| None | 2667 (100.0) | 52.2 | 15.5 | 14.2 | 5.6 | 4.0 | 8.5 |
| Mild | 4091 (100.0) | 41.6 | 21.5 | 18.3 | 5.8 | 4.3 | 8.4 |
| Moderate | 887 (100.0) | 37.1 | 25.7 | 15.2 | 7.7 | 6.1 | 8.2 |
| Severe | 309 (100.0) | 29.2 | 20.4 | 14.8 | 11.6 | 9.9 | 14.0 |
| Unknown | 275 (100.0) | 22.2 | 22.3 | 4.7 | 26.4 | 6.5 | 17.8 |
| Stage | |||||||
| Tx-T0 | 224 (100.0) | 59.3 | 7.4 | 1.0 | 16.8 | 1.0 | 14.4 |
| T1 | 5275 (100.0) | 42.4 | 19.6 | 17.8 | 5.2 | 5.1 | 10.0 |
| T2 | 2730 (100.0) | 44.7 | 21.5 | 13.8 | 9.4 | 4.2 | 6.4 |
| PSA group | |||||||
| < 4 | 901 (100.0) | 55.8 | 11.9 | 13.5 | 3.0 | 5.8 | 10.1 |
| 4–10 | 4824 (100.0) | 46.7 | 18.9 | 19.8 | 3.6 | 4.4 | 6.6 |
| > 10 | 2075 (100.0) | 29.8 | 29.1 | 10.0 | 17.5 | 4.3 | 9.3 |
| Unknown | 429 (100.0) | 41.9 | 7.0 | 3.8 | 5.8 | 6.4 | 35.0 |
| Gleason Score group | |||||||
| 2–6 | 4249 (100.0) | 39.5 | 18.3 | 20.5 | 4.6 | 6.4 | 10.6 |
| 7 | 2946 (100.0) | 52.0 | 20.6 | 11.9 | 6.8 | 2.5 | 6.2 |
| 8–10 | 956 (100.0) | 39.6 | 25.7 | 7.5 | 17.7 | 2.0 | 7.5 |
| Unknown | 78 (100.0) | 7.6 | 10.7 | 17.7 | 8.8 | 19.8 | 35.4 |
| NCCN risk group | |||||||
| Low complete | 2966 (100.0) | 42.7 | 15.8 | 23.0 | 2.9 | 6.5 | 9.0 |
| Low missing† | 273 (100.0) | 27.9 | 5.3 | 7.3 | 3.2 | 12.4 | 43.9 |
| Intermediate | 3491 (100.0) | 49.4 | 21.8 | 13.7 | 5.4 | 3.2 | 6.5 |
| High | 1499 (100.0) | 34.3 | 27.1 | 7.6 | 19.9 | 2.7 | 8.4 |
*
Weighted percentages.
†
T1-2a and either PSA < 10 OR Gleason Score <7 with the other variable unknown.
AS indicates active surveillance; BT, brachytherapy; EBRT, external beam radiation therapy; NT, no therapy; PADT, primary androgen deprivation therapy; RP, radical prostatectomy.